03.27.14
Sunnyvale, Calif.-based Accuray Inc. has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare for its Cyberknife M6 system to treat radiation therapy patients. The system, which will be marketed in Japan as the “Cyberknife M6 Series,” offers a wide range of motion and high-precision conformal delivery available and enables patients to lie comfortably and breathe freely while receiving precise, high dose radiation therapy in a relatively short number of treatments, reducing side effects and preserving quality of life, the company claims.
The Cyberknife system is a robotic full-body radiosurgery system optimized to deliver stereotactic radiosurgery and stereotactic body radiation therapy non-invasively throughout the body.
The Cyberknife system is designed to enable physicians to precisely maximize dose, minimize side effects and maximize patient comfort. It automatically adjusts the beam for target movement, enabling reduced margins and minimizing radiation exposure to healthy tissue and critical organs. The idea is that patients treated with the Cyberknife system should not experience the discomfort of breath-holding, abdominal compression, breathing apparatus, or metal head-frames typically associated with other radiation therapy devices.
“At Accuray, we understand the priority that our customers place on advanced medical technology and patient comfort,” said Juki Hozumi, president and general manager of Accuray Japan. “We are committed to excellence in service, support and education that will enable our customers to optimize their use of our leading-edge tumor treatments long-term.”
“This marks a key milestone in our strategic growth plan for the market in Japan,” said President and CEO Joshua H. Levine. “We are very pleased to provide the latest Cyberknife technology to our customers and their patients in Japan. The Cyberknife M6 Series offers advantages of increased clinical flexibility, greatly reduced treatment times and ease of use for clinicians, while providing patients the most precise tumor treatment available.”
In July 2010, Accuray was granted Shonin approval of the Cyberknife G4 System for use in Japan in the treatment of tumors in the body, inclusive of the head and neck; and in 2012, Shonin approval was granted to market the Cyberknife VSI system for robotic radiosurgery.
Accuray is a radiation oncology company that makes precise tumor treatment solutions.
The Cyberknife system is a robotic full-body radiosurgery system optimized to deliver stereotactic radiosurgery and stereotactic body radiation therapy non-invasively throughout the body.
The Cyberknife system is designed to enable physicians to precisely maximize dose, minimize side effects and maximize patient comfort. It automatically adjusts the beam for target movement, enabling reduced margins and minimizing radiation exposure to healthy tissue and critical organs. The idea is that patients treated with the Cyberknife system should not experience the discomfort of breath-holding, abdominal compression, breathing apparatus, or metal head-frames typically associated with other radiation therapy devices.
“At Accuray, we understand the priority that our customers place on advanced medical technology and patient comfort,” said Juki Hozumi, president and general manager of Accuray Japan. “We are committed to excellence in service, support and education that will enable our customers to optimize their use of our leading-edge tumor treatments long-term.”
“This marks a key milestone in our strategic growth plan for the market in Japan,” said President and CEO Joshua H. Levine. “We are very pleased to provide the latest Cyberknife technology to our customers and their patients in Japan. The Cyberknife M6 Series offers advantages of increased clinical flexibility, greatly reduced treatment times and ease of use for clinicians, while providing patients the most precise tumor treatment available.”
In July 2010, Accuray was granted Shonin approval of the Cyberknife G4 System for use in Japan in the treatment of tumors in the body, inclusive of the head and neck; and in 2012, Shonin approval was granted to market the Cyberknife VSI system for robotic radiosurgery.
Accuray is a radiation oncology company that makes precise tumor treatment solutions.